3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
1
Gastrointestinal
1
Conditions
Stomach Neoplasms
6
Esophageal Neoplasms
4
Gastrointestinal Neoplasms
3
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Adenocarcinoma
2
Solid Tumor
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Neoplasms, Unknown Primary
1
Nasopharyngeal Carcinoma
1
Locally Advanced Gastric Adenocarcinoma
1
Hand-Foot Syndrome
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Biliary Tract Neoplasms
1
Bile Duct Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
Oxaliplatin
32
Fluorouracil
24
Gemcitabine
23
Leucovorin
19
Docetaxel
19
pembrolizumab
17
Capecitabine
15
Radiotherapy
14
Irinotecan
13
Cisplatin
11
Bevacizumab
11
Nivolumab
8
130-nm albumin-bound paclitaxel
8
Trastuzumab
7
Erlotinib Hydrochloride
7
Cyclophosphamide
7
Albumin-Bound Paclitaxel
7
Radiosurgery
6
Paclitaxel
6
Taxes
5
S 1 (combination)
5
Metformin
5
Carboplatin
5
Blood Specimen Collection
5
Sunitinib
4
Sorafenib
4
Pemetrexed
4
Esophagectomy
4
Chemoradiotherapy
4
Cetuximab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Adenocarcinoma
×
tegafur-gimeracil-oteracil
×
Clear all
NCT05161572
2025-06-18
NeoRacing
Fudan University
Phase 2
Terminated
6 enrolled
NCT02564367
2021-04-29
S-1 adjuvant
AIO-Studien-gGmbH
Phase 1/2
Completed
30 enrolled